Brief: Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia with Neurocrine Biosciences
26/02/2024 12:06
Feb 26 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS ANNOUNCES SELECTION OF GENE THERAPY
DEVELOPMENT CANDIDATE FOR FRIEDREICH’S ATAXIA IN COLLABORATION
WITH NEUROCRINE BIOSCIENCES, TRIGGERING MILESTONE PAYMENT
* VOYAGER THERAPEUTICS: SELECTION OF DEVELOPMENT CANDIDATE
TRIGGERED $5 MILLION MILESTONE PAYMENT TO CO, EXPECTS TO RECEIVE
IN Q1 2024
* VOYAGER THERAPEUTICS : CO ELIGIBLE TO RECEIVE ADDITIONAL
FUTURE
MILESTONE PAYMENTS BASED ON FURTHER ADVANCEMENT
Source text for Eikon: ID:nGNX8hBsr9
Further company coverage: VYGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview